Skip to main content
. 2022 Sep 29;10(9):e005052. doi: 10.1136/jitc-2022-005052

Figure 1.

Figure 1

Flow cytometry and RNA sequencing analysis of tumor tissue. (A) Number of CD8+T cells and (B) number of CD4+T cells in tumor tissue as assessed by flow cytometry of fresh tumor tissue. (C)- Number of CD8+T cells (left) and CD4+T cells (right) in pretreatment tumor tissue. (D) CIBERSORT predicted (bulk RNA-sequencing) enrichment of CD8+T cells and active memory CD4+T cells in pretreatment tumor tissue Please see online supplemental figure S1 for full heatmap of CIBERSORT enrichment scores for each patient. Patients in red have current median PFS 2.3 years compared with patients in black text with median PFS 1.6 months. PFS, progression-free survival.